Description of Patients With Type 1 Diabetes Treated With Teplizumab
Public ClinicalTrials.gov record NCT06892002. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Real-World Observational Study Characterizing Patients With Type 1 Diabetes Treated With Teplizumab
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease caused by the destruction of pancreatic β cells. T1D pathogenesis progresses through several stages: Stage 1 T1D includes the presence of β cell autoimmunity and thus presence of islet autoantibodies, without the presence of dysglycemia and symptoms. Stage 2 T1D includes the presence of islet autoantibodies and dysglycemia, also with no symptoms. Stage 3 T1D includes presence of islet autoantibodies, overt hyperglycemia, and symptoms; most patients with Stage 3 T1D meet standard diagnostic criteria for diabetes and require insulin treatment. Teplizumab has been shown to delay progression to Stage 3 in participants at Stage 2 in a Phase 2 clinical trial, leading to subsequent approval in the United States of America (USA). Patients outside of the USA are able to receive the treatment through Pre-Registration Import Licenses and Managed Access Programs. The current study will collect data on the use of teplizumab in routine care, to better understand which patients received teplizumab and how these patients were managed after they received the treatment.
Study identification
- NCT ID
- NCT06892002
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 110 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 10, 2025
- Primary completion
- Aug 4, 2025
- Completion
- Aug 4, 2025
- Last update posted
- Aug 14, 2025
2025
United States locations
- U.S. sites
- 24
- U.S. states
- 15
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arkansas Children's Hospital Research Institute | Little Rock | Arkansas | 72202 | — |
| University of California, San Francisco | San Francisco | California | 94158 | — |
| Barbara Davis Center For Childhood Diabetes | Aurora | Colorado | 80045 | — |
| Children's National Medical Center | Washington D.C. | District of Columbia | 20010 | — |
| University of Miami Medical Center | Miami | Florida | 33136 | — |
| USF Diabetes Center | Tampa | Florida | 33612 | — |
| Doctor's Clinic | Vero Beach | Florida | 32960 | — |
| Atlanta Diabetes Associates | Atlanta | Georgia | 30318 | — |
| Childrens Healthcare of Atlanta | Atlanta | Georgia | 30329 | — |
| Riley Hospital for Children | Carmel | Indiana | 46032 | — |
| University of Louisville | Louisville | Kentucky | 40202 | — |
| Boston Children's Hospital Division of Endocrinology | Boston | Massachusetts | 02115 | — |
| Atlantic Health | Morristown | New Jersey | 07960 | — |
| Hassenfeld Children's Hospital at NYU Langone | New York | New York | 10016 | — |
| Morgan Stanley Children's Hospital | New York | New York | 10032 | — |
| Ten's Medical PC | Staten Island | New York | 10306 | — |
| SUNY Upstate Medical University PARENT | Syracuse | New York | 13210 | — |
| Sanford Research/USD | Fargo | North Dakota | 58122 | — |
| AM Diabetes & Endocrinology Center | Bartlett | Tennessee | 38133 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| El Paso Medical Research Institute | El Paso | Texas | 79902-4646 | — |
| University of Utah Hospitals & Clinics | Salt Lake City | Utah | 84108 | — |
| Diabetes and Endocrine Treatment Specialists | Sandy City | Utah | 84093 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06892002, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 14, 2025 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06892002 live on ClinicalTrials.gov.